GcMAF in Israel: Availability and Regulatory Status

GcMAF (Gc protein-derived macrophage activating factor) is not approved by the Israeli Ministry of Health (or any major regulatory agency — FDA, EMA, Health Canada) for the treatment of cancer or any other condition.

Regulatory Status

• Israel: Not registered as a drug; cannot be legally marketed, sold, or prescribed for therapeutic use.
• International: Multiple warnings issued (FDA, EMA, UK MHRA, TGA Australia) against clinics selling unproven GcMAF products.
• Scientific evidence: No rigorous RCTs demonstrate efficacy for cancer. Early studies (Yamamoto et al.) were small, uncontrolled, and retracted or disputed.

Risks of Unregulated Use

• Unknown purity, sterility, potency (often produced in non-GMP settings).
• Potential for contamination (viral, prion, bacterial).
• Delay of evidence-based treatment.
• Financial exploitation of vulnerable patients.

Patient Guidance

• Discuss all therapies with your oncologist.
• Seek treatment within clinical trials or approved protocols.
• Report unlicensed cancer treatments to the Ministry of Health.

GcMAF remains an investigational compound without regulatory approval. Its use outside clinical trials is not supported by evidence and poses safety and legal risks.